BST2

Across TCGA pan-cancer cohorts, BST2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BST2 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BST2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BST2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where BST2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.632	0.374	.005	13	view →
COAD	DFS	Quartile	II,III,IV	0.888	1.000	.037	12	view →
CCRCC	DFS	Tertile	All	0.584	0.883	.013	12	view →
HNSC	OS	Median	All	1.000	0.484	.038	6	view →
LSCC	DFS	Median	All	0.823	0.504	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BST2–PDAC (OS)

Open the PDAC breakdown →